- Home
- LPTX
as 12-18-2024 10:39am EST
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 99.5M | IPO Year: | N/A |
| Target Price: | $7.50 | AVG Volume (30 days): | 437.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.68 - $5.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Leap Therapeutics Inc. News
LPTX Breaking Stock News: Dive into LPTX Ticker-Specific Updates for Smart Investing
PR Newswire
22 days ago
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
PR Newswire
a month ago
Leap Therapeutics Reports Third Quarter 2024 Financial Results
PR Newswire
3 months ago
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
PR Newswire
4 months ago
Leap Therapeutics Reports Second Quarter 2024 Financial Results
The Telegraph
6 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Simply Wall St.
6 months ago
It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
Simply Wall St.
6 months ago
Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
Simply Wall St.
6 months ago
Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks
Compare LPTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LPTX Leap Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.